TABLE 4.
Yr | % Susceptible
|
|||||
---|---|---|---|---|---|---|
S. aureus, oxacillin |
S. pneumoniaeb
|
|||||
Penicillin | Cefotaxime | Ceftriaxone | Erythromycin | Clindamycin | ||
1995 | 64 | 70 | 83 | 81 | 91 | NAc |
1996 | 58 | 63 | 80 | 85 | 82 | NA |
1997 | 58 | 62 | 79 | 83 | 70 | NA |
1998 | 54 | 57 | 78 | 91 | 69 | NA |
1999 | 51 | 57 | 75 | 92 | 64 | 86 |
2000 | 43 | 51 | 79 | 90 | 65 | 94 |
2001 | 59 | 49 | 75 | 93 | 52 | 85 |
Data for 1995 to 2000 are cumulative published (4) and unpublished data excluding pediatric isolates.
Cefotaxime and ceftriaxone results were calculated by using meningeal breakpoints (≤1, 2, and ≥4 μg/ml) prior to implementation of 2002 NCCLS breakpoint changes for nonmeningeal isolates (11).
NA, not available.